Petros Pharmaceuticals annual operating margin
2020
2021
2022
2023
2024
Petros Pharmaceuticals's operating margin was −90.51% for fiscal 2024.
View full Petros Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −90.51% | +143.37 pp |
| 2023 | 2023-12-31 | −233.88% | +98.49 pp |
| 2022 | 2022-12-31 | −332.37% | −101.32 pp |
| 2021 | 2021-12-31 | −231.05% | −50.27 pp |
| 2020 | 2020-12-31 | −180.78% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2024 | 2024-12-31 | −79.62% | +207.40 pp |
| Q3 2024 | 2024-09-30 | −75.96% | +47.55 pp |
| Q2 2024 | 2024-06-30 | −94.91% | −42.91 pp |
| Q1 2024 | 2024-03-31 | −108.22% | +392.81 pp |
| Q3 2023 | 2023-09-30 | −287.02% | −247.34 pp |
| Q2 2023 | 2023-06-30 | −123.51% | −103.99 pp |
| Q1 2023 | 2023-03-31 | −52.00% | +115.66 pp |
| Q3 2022 | 2022-09-30 | −501.03% | −326.85 pp |
| Q2 2022 | 2022-06-30 | −39.69% | +14.23 pp |
| Q1 2022 | 2022-03-31 | −19.52% | +127.89 pp |
| Q3 2021 | 2021-09-30 | −167.66% | −100.23 pp |
| Q2 2021 | 2021-06-30 | −174.18% | +191.17 pp |
| Q1 2021 | 2021-03-31 | −53.92% | +259.12 pp |
| Q4 2020 | 2020-12-31 | −147.41% | — |
| Q3 2020 | 2020-09-30 | −67.44% | — |
| Q2 2020 | 2020-06-30 | −365.35% | — |
| Q1 2020 | 2020-03-31 | −313.03% | — |
Across the available reported history, Petros Pharmaceuticals's operating margin increased from −233.88% to −90.51%, a change of +143.37 percentage points. The latest reported quarter, Q4 2024, shows −79.62%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals filings at SEC.gov ↗